Evidence map›Paper›PMID 35228432›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Liver Biopsy-confirmed Primary Hepatic Amyloidosis with Only Jaundice As the Initial Symptom: An Autopsy Case Report.

Hirotsugu Ueno, Akitoshi Douhara, Yui Osaki, Aritoshi Koizumi, Nobuyuki Yorioka, Shigehiko Ueda, Masahiro Tsutsumi, Hitoshi Yoshiji

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. [Analysis of clinical manifestations and prognosis of primary systemic light chain amyloidosis with liver involvement].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hirotsugu UenoDepartment of Gastroenterology, Saiseikai Chuwa Hospital, Japan.
Akitoshi DouharaDepartment of Gastroenterology, Saiseikai Chuwa Hospital, Japan.
Yui OsakiDepartment of Gastroenterology, Saiseikai Chuwa Hospital, Japan.
Aritoshi KoizumiDepartment of Gastroenterology, Saiseikai Chuwa Hospital, Japan.
Nobuyuki YoriokaDepartment of Gastroenterology, Saiseikai Chuwa Hospital, Japan.
Shigehiko UedaDepartment of Gastroenterology, Saiseikai Chuwa Hospital, Japan.
Masahiro TsutsumiDepartment of Pathology, Saiseikai Chuwa Hospital, Japan.
Hitoshi YoshijiDepartment of Gastroenterology, Nara Medical University, Japan.
Jikei University Kashiwa hospital · JPNara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloidosis causes various symptoms in many organs of the body, but amyloidosis that presents with liver damage alone has never been reported. We treated an 83-year-old man with amyloidosis who presented with liver damage alone. The liver damage in this patient was histologically proven to be liver amyloidosis. The administration of bortezomib and dexamethasone was not effective, so he rapidly died of liver failure. An aggressive liver biopsy should be considered when unexplained jaundice is observed.

Indexed as

AmyloidosisJaundiceLiver DiseasesAged, 80 and overAutopsyBiopsyBortezomibHumansMaleBortezomibamyloidosisbortezomibjaundiceliver biopsy

Identifiers

PMID35228432
PMCPMC9593147
OpenAlexW4214770628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.